Frost & Sullivan Independent Equity Research

Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.

kadimastem

Company: Kadimastem Ltd.        

Sector: Biotechnology

Report type: H1-2018 Update

Published on: 27 September, 2018

Kadimastem research articles:

Close Menu
Font Resize